However, although the CML study I suggested that IFN in association with HU was superior to IFN alone [8], a successive German investigation demonstrated no benefit of using HU in combination with IM over IM monotherapy [13]. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.